Prognostic value of the aminopyrine breath test in cirrhotic patients. 1986

J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau

The aminopyrine breath test has been proposed as a quantitative test of hepatic function, but its long-term prognostic value in patients with cirrhosis has not been determined. The aim of this study was to examine the usefulness of the aminopyrine breath test in assessing prognosis and to compare it with traditional methods of evaluating liver function. One-hundred eighty-seven patients with histologically confirmed cirrhosis were studied prospectively. An aminopyrine breath test was obtained at the time of inclusion in the study and results were expressed as per cent of the dose excreted in 2 hr. At inclusion, the severity of liver disease was also assessed according to the Pugh modification of the Child-Turcotte classification based on ascites, neurological status, serum albumin, serum bilirubin and prothrombin time. Mean follow-up was 844 days. During that period, 59 of 187 patients died of their liver disease. Two-year survival decreased with increasing Child-Turcotte classification score: survival was 98% in Child Class A patients (n = 62), 66% in Child Class B (n = 76) and 36% in Child Class C (n = 49) (chi 2 = 65.6, p less than 0.001). Two-year survival also decreased significantly with increasing degree of aminopyrine breath test abnormalities: survival was 90% in patients with aminopyrine breath test greater than 4% (n = 56); 78% in patients with aminopyrine breath test = 2 to 4% (n = 66), and 43% in patients with aminopyrine breath test less than 2% (n = 65) (chi 2 = 36.9, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008111 Liver Function Tests Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions. Function Test, Liver,Function Tests, Liver,Liver Function Test,Test, Liver Function,Tests, Liver Function
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001944 Breath Tests Any tests done on exhaled air. Breathalyzer Tests,Breath Test,Breathalyzer Test,Test, Breath,Test, Breathalyzer,Tests, Breath,Tests, Breathalyzer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000632 Aminopyrine A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS. Amidophenazon,Aminophenazone,Dimethylaminophenazone,Dipyrine,Amidazophen,Amidophen,Amidopyrine,Aminofenazone,Dimethyl-N-aminoantipyrine,Dimethylaminoantipyrine,Eufibron,Dimethyl N aminoantipyrine

Related Publications

J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau
January 1991, Digestion,
J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau
June 1992, Gut,
J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau
January 1983, Hepatology (Baltimore, Md.),
J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau
November 1994, Digestive diseases and sciences,
J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau
January 1994, The Italian journal of gastroenterology,
J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau
November 2004, Transplant international : official journal of the European Society for Organ Transplantation,
J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau
September 1991, Digestive diseases and sciences,
J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau
April 1990, Nuclear medicine communications,
J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau
April 1986, Archives of internal medicine,
J P Villeneuve, and C Infante-Rivard, and M Ampelas, and G Pomier-Layrargues, and P M Huet, and D Marleau
July 1995, Digestive diseases and sciences,
Copied contents to your clipboard!